Could vitamins a and B3 shield kidney transplant patients from skin cancer?

NCT ID NCT05702398

Recruiting now Prevention Sponsor: Rhode Island Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether taking vitamin A and nicotinamide (a form of vitamin B3) can safely raise blood levels in kidney transplant recipients who have had skin cancer. Thirty participants will take these vitamins or a placebo for six months. The goal is to see if this approach is feasible for a larger future study aimed at preventing skin cancer in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vitamin A (retinyl palmitate) and nicotinamide (vitamin B3)
What this could lead to: If successful, this could point toward a simple vitamin-based approach to help prevent skin cancer in kidney transplant recipients.
What could go wrong: This is a very early pilot study with only 30 participants, so results may not apply to everyone. It only checks blood levels, not whether skin cancer is actually prevented.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

skin cancer skin neoplasm skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT RECIPIENTS SKIN CANCER

Contacts and locations

Locations

Rhode Island Hospital
RECRUITING

Providence, Rhode Island, 02912, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.